Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Thursday it has begun discussions with the U.S. government to launch ...

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...